The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma

July 3, 2014
Julian Adams, PhD

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Clinical Pearls

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma. This trial, labeled DYNAMO, was presented at the 2014 ASCO Annual Meeting.

  • In the course of a phase I investigation of IPI-145, patients with indolent lymphoma were enrolled.
  • The overall response rate of this group was 73%. The complete response rate was 20%.
  • These results were compelling enough to enroll a single-arm study of 120 patients with refractory indolent non-Hodgkin lymphoma. The trial is ongoing.